RU2006127422A - Антимикробные консерванты для достижения мультидозовых рецептур с использованием бета-циклодекстринов для жидких лекарственных форм - Google Patents
Антимикробные консерванты для достижения мультидозовых рецептур с использованием бета-циклодекстринов для жидких лекарственных форм Download PDFInfo
- Publication number
- RU2006127422A RU2006127422A RU2006127422/15A RU2006127422A RU2006127422A RU 2006127422 A RU2006127422 A RU 2006127422A RU 2006127422/15 A RU2006127422/15 A RU 2006127422/15A RU 2006127422 A RU2006127422 A RU 2006127422A RU 2006127422 A RU2006127422 A RU 2006127422A
- Authority
- RU
- Russia
- Prior art keywords
- composition according
- pharmaceutical composition
- cyclodextrin
- preservative
- pharmaceutically acceptable
- Prior art date
Links
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/724—Cyclodextrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Nanotechnology (AREA)
- Inorganic Chemistry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Dermatology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Cosmetics (AREA)
Claims (10)
1. Фармацевтическая композиция, содержащая терапевтически эффективное количество активного фармацевтического ингредиента, β-циклодекстрин, фармацевтически приемлемый консервант, фармацевтически приемлемый носитель и необязательный фармацевтически приемлемый эксципиент, в которой консервант демонстрирует фармацевтически приемлемую антимикробную консервирующую эффективность.
2. Фармацевтическая композиция по п.1, в которой активный фармацевтический ингредиент представляет собой соединение формулы I
или его фармацевтически приемлемую соль, в которой R2 выбирают из группы, состоящей из метила, этила, изопропила, втор-бутила и трет-бутила.
3. Фармацевтическая композиция по п.1 или 2, в которой β-циклодекстрин представляет собой 2-гидроксипропил-β-циклодекстрин или сульфобутиловый эфир β-циклодекстрина.
4. Фармацевтическая композиция по п.1 или 2, в которой консервант выбирают из тимерозала, пропиленгликоля, фенола или мета-крезола или их комбинации.
5. Фармацевтическая композиция по п.1 или 2, в которой консервант имеет величину связывания с циклодекстрином, меньшую, чем величина связывания активного фармацевтического ингредиента с циклодекстрином.
6. Фармацевтическая композиция по п.1 или 2, в которой от примерно 1 мг/мл до примерно 5 мг/мл консерванта не связано с циклодекстрином.
7. Фармацевтическая композиция по п.1 или 2, в которой величина связывания активного фармацевтического ингредиента с циклодекстрином находится между 500 М-1 и 10000 М-1.
8. Фармацевтическая композиция по п.1 или 2 для использования в качестве лекарства.
9. Применение композиции по п.2 для производства лекарства для лечения заболевания, для которого требуется применение антагониста нейрокининового рецептора.
10. Способ лечения заболевания, для которого требуется применение антагониста нейрокининового рецептора, у млекопитающих, предусматривающий введение указанному млекопитающему терапевтически эффективного количества фармацевтической композиции по п.2.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US54089704P | 2004-01-30 | 2004-01-30 | |
| US60/540,897 | 2004-01-30 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2006127422A true RU2006127422A (ru) | 2008-03-10 |
| RU2332997C2 RU2332997C2 (ru) | 2008-09-10 |
Family
ID=34910697
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2006127422/15A RU2332997C2 (ru) | 2004-01-30 | 2005-01-17 | АНТИМИКРОБНЫЕ КОНСЕРВАНТЫ ДЛЯ ДОСТИЖЕНИЯ МУЛЬТИДОЗОВЫХ РЕЦЕПТУР С ИСПОЛЬЗОВАНИЕМ β-ЦИКЛОДЕКСТРИНОВ ДЛЯ ЖИДКИХ ЛЕКАРСТВЕННЫХ ФОРМ |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US8183230B2 (ru) |
| EP (1) | EP1713504B1 (ru) |
| JP (1) | JP5021318B2 (ru) |
| KR (1) | KR100834232B1 (ru) |
| CN (1) | CN101090735A (ru) |
| AR (2) | AR047469A1 (ru) |
| AU (1) | AU2005216709B2 (ru) |
| BR (1) | BRPI0506496B8 (ru) |
| CA (1) | CA2554346C (ru) |
| CO (1) | CO5700794A2 (ru) |
| CY (1) | CY1119188T1 (ru) |
| DK (1) | DK1713504T3 (ru) |
| ES (1) | ES2638113T3 (ru) |
| HU (1) | HUE034099T2 (ru) |
| IL (1) | IL176676A0 (ru) |
| LT (1) | LT1713504T (ru) |
| NO (1) | NO20063858L (ru) |
| NZ (1) | NZ548236A (ru) |
| PL (1) | PL1713504T3 (ru) |
| PT (1) | PT1713504T (ru) |
| RU (1) | RU2332997C2 (ru) |
| SI (1) | SI1713504T1 (ru) |
| TW (1) | TW200524632A (ru) |
| WO (1) | WO2005082416A2 (ru) |
| ZA (1) | ZA200605148B (ru) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2013273764B2 (en) * | 2011-11-29 | 2016-05-05 | Zoetis Services Llc | Pharmaceutical compositions |
| BR112014012985B1 (pt) | 2011-11-29 | 2020-05-12 | Jurox Pty Ltd | Composição farmacêutica injetável, seu método de produção e uso, bem como método de conservação de uma composição farmacêutica injetável e uso de pelo menos um co-solvente e pelo menos um conservante |
| PL3021832T3 (pl) * | 2013-07-19 | 2021-08-23 | Boehringer Ingelheim Vetmedica Gmbh | Konserwowana ciekła wodna kompozycja farmaceutyczna zawierająca eteryfikowane pochodne cyklodekstryny |
| NL2015865B1 (en) | 2015-11-27 | 2017-06-13 | Le Vet B V | Maropitant Formulation. |
| EA201992414A1 (ru) | 2017-04-10 | 2020-03-16 | Чейс Терапьютикс Корпорейшн | Комбинация nk1-антагониста и способ лечения синуклеинопатий |
| MA49524A (fr) | 2017-06-30 | 2021-05-26 | Chase Therapeutics Corp | Compositions d'antagoniste de nk-1 et méthodes destinées à être utilisées dans le traitement de la dépression |
| WO2020167476A1 (en) | 2019-02-15 | 2020-08-20 | Saol International Limited | Injectable phenol formulations and methods of their use |
| EP3725298A1 (en) | 2019-04-16 | 2020-10-21 | Faes Farma, S.A. | Stable and preserved pharmaceutical compositions of bilastine |
| CN112370451A (zh) * | 2020-12-08 | 2021-02-19 | 河北科技大学 | 一种枸橼酸马罗匹坦包合物、注射液及制备方法 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5910510A (ja) * | 1982-07-08 | 1984-01-20 | Nippon Zenyaku Kogyo Kk | 低刺激性チアムリン注射剤 |
| JPS59152320A (ja) * | 1983-02-17 | 1984-08-31 | Takeda Chem Ind Ltd | 水性製剤 |
| JPS6419737A (en) * | 1987-07-15 | 1989-01-23 | Hitachi Ltd | Multilayer interconnection tape carrier |
| JPH039848A (ja) * | 1989-06-06 | 1991-01-17 | Canon Inc | 液体噴射記録装置 |
| US5807867A (en) * | 1991-05-31 | 1998-09-15 | Pfizer Inc. | Quinuclidine derivatives |
| US5602112A (en) * | 1992-06-19 | 1997-02-11 | Supergen, Inc. | Pharmaceutical formulation |
| EP0668863B1 (en) * | 1992-11-12 | 1997-01-08 | Pfizer Inc. | Quinuclidine derivative as substance p antagonist |
| US5393762A (en) * | 1993-06-04 | 1995-02-28 | Pfizer Inc. | Pharmaceutical agents for treatment of emesis |
| WO2000012137A1 (en) | 1998-09-02 | 2000-03-09 | Allergan Sales, Inc. | Preserved cyclodextrin-containing compositions |
| US6255320B1 (en) * | 1999-06-01 | 2001-07-03 | Pfizer Inc. | Polymorphs of a crystalline azo-bicyclo (2,2,2) octan-3-amine citrate and their pharmaceutical compositions |
| WO2001001955A1 (en) | 1999-07-02 | 2001-01-11 | Janssen Pharmaceutica N.V. | Nasal formulation of an antifungal |
| US7163681B2 (en) * | 2000-08-07 | 2007-01-16 | Centocor, Inc. | Anti-integrin antibodies, compositions, methods and uses |
| US20030055023A1 (en) * | 2001-03-20 | 2003-03-20 | Rajewski Roger A. | Formulations containing etomidate and a sulfoalkyl ether cyclodextrin |
| US7034013B2 (en) * | 2001-03-20 | 2006-04-25 | Cydex, Inc. | Formulations containing propofol and a sulfoalkyl ether cyclodextrin |
| HUP0401154A2 (hu) * | 2001-07-20 | 2004-10-28 | Pfizer Products Inc. | NK-1 receptor antagonisták használata kutyák, macskák és lovak nemkívánatos viselkedésének módosítására |
| MXPA04008173A (es) | 2002-02-22 | 2004-11-26 | Pharmacia Corp | Formulaciones de farmaco antibiotico oftalmico que contienen un compuesto de ciclodextrina y cloruro de cetil piridinio. |
| US6869939B2 (en) | 2002-05-04 | 2005-03-22 | Cydex, Inc. | Formulations containing amiodarone and sulfoalkyl ether cyclodextrin |
| DE10228049A1 (de) | 2002-06-24 | 2004-01-15 | Merck Patent Gmbh | Flüssige Zubereitung enthaltend Oligopeptide |
| US6861526B2 (en) * | 2002-10-16 | 2005-03-01 | Pfizer Inc. | Process for the preparation of (S,S)-cis-2-benzhydryl-3-benzylaminoquinuclidine |
| BRPI0507325A (pt) | 2004-01-30 | 2007-07-03 | Pfizer Prod Inc | antagonistas dos receptores nk-1 para melhorar a recuperação da anestesia |
| MXPA06008648A (es) | 2004-01-30 | 2006-09-04 | Pfizer Prod Inc | Composiciones farmaceuticas de antagonistas del receptor de neuroquinina y ciclodextrina y metodos para una tolerancia mejorada en el sitio de inyeccion. |
| PL1713801T3 (pl) | 2004-02-02 | 2008-04-30 | Pfizer Products Incorporated | Sposób wytwarzania 1-(2S,3S)-2-benzhydrylo-N-(5-tert-butylo-2-metoksybenzylo)chinuklidyno-3-aminy |
-
2005
- 2005-01-17 LT LTEP05702263.4T patent/LT1713504T/lt unknown
- 2005-01-17 WO PCT/IB2005/000100 patent/WO2005082416A2/en active Application Filing
- 2005-01-17 AU AU2005216709A patent/AU2005216709B2/en active Active
- 2005-01-17 PT PT57022634T patent/PT1713504T/pt unknown
- 2005-01-17 SI SI200532166T patent/SI1713504T1/sl unknown
- 2005-01-17 DK DK05702263.4T patent/DK1713504T3/en active
- 2005-01-17 EP EP05702263.4A patent/EP1713504B1/en active Active
- 2005-01-17 ES ES05702263.4T patent/ES2638113T3/es active Active
- 2005-01-17 RU RU2006127422/15A patent/RU2332997C2/ru not_active IP Right Cessation
- 2005-01-17 PL PL05702263T patent/PL1713504T3/pl unknown
- 2005-01-17 NZ NZ548236A patent/NZ548236A/en unknown
- 2005-01-17 JP JP2006550330A patent/JP5021318B2/ja active Active
- 2005-01-17 CN CNA2005800032849A patent/CN101090735A/zh active Pending
- 2005-01-17 US US10/588,070 patent/US8183230B2/en active Active
- 2005-01-17 HU HUE05702263A patent/HUE034099T2/en unknown
- 2005-01-17 BR BRPI0506496A patent/BRPI0506496B8/pt active IP Right Grant
- 2005-01-17 KR KR1020067015283A patent/KR100834232B1/ko active IP Right Grant
- 2005-01-17 CA CA002554346A patent/CA2554346C/en active Active
- 2005-01-27 AR ARP050100283A patent/AR047469A1/es not_active Application Discontinuation
- 2005-01-28 TW TW094102680A patent/TW200524632A/zh unknown
-
2006
- 2006-06-22 ZA ZA200605148A patent/ZA200605148B/en unknown
- 2006-07-03 IL IL176676A patent/IL176676A0/en unknown
- 2006-07-26 CO CO06073023A patent/CO5700794A2/es not_active Application Discontinuation
- 2006-08-29 NO NO20063858A patent/NO20063858L/no not_active Application Discontinuation
-
2017
- 2017-08-04 CY CY20171100843T patent/CY1119188T1/el unknown
- 2017-08-16 AR ARP170102291A patent/AR109357A2/es not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2006127422A (ru) | Антимикробные консерванты для достижения мультидозовых рецептур с использованием бета-циклодекстринов для жидких лекарственных форм | |
| RU2470016C2 (ru) | Производное бипиразола | |
| JP2007519703A5 (ru) | ||
| EA200801165A1 (ru) | Антагонисты неосновного рецептора-1 меланинконцентрирующего гормона | |
| IL274058A (en) | Treatment of inflammatory lesions of rosacea with ivermectin | |
| US20050085446A1 (en) | Fluoroquinolone formulations and methods of making and using the same | |
| AR048336A1 (es) | Hidrocloruro de (4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il)-(4-bromo-3-metil-5-propoxi-tiofen-2-il)-metanona como un inhibidor de la triptasa de mastocitos | |
| JP2009542657A5 (ru) | ||
| CO6331425A2 (es) | Composiciones que comprenden n-(3,4-difluoro-2-(2-fluoro-4-yodofenilamino)6-metoxifenil)-1-(2,3-dihidroxiproxipropil)ciclopropan-1-sulfamida | |
| JP2001187728A (ja) | 眼科用組成物 | |
| CA2574450A1 (en) | Method of treating hyperphosphataemia using lanthanum hydroxycarbonate | |
| JP2019517587A5 (ru) | ||
| RU2009123536A (ru) | Стабильные парентеральные составы, включающие ингибиторы pcb на основе бензодиазепина | |
| JP2014521641A5 (ru) | ||
| NI202100031A (es) | Formulación basada en ciclodextrina de un inhibidor de bcl-2 | |
| BRPI0418742A (pt) | métodos de tratamento, prevenção ou controle de uma sìndrome mielodisplásica, de redução ou evitação de um efeito adverso associado com a administração de um segundo ingrediente ativo em um paciente sofrendo de um sìndrome mielodisplásica, composição farmacêutica, forma de dosagem unitária única, e, kit | |
| DE602004009552D1 (de) | Orales abgabesystem mit einem antibakteriellen und einem entzündungshemmenden mittel | |
| AU2003240113B2 (en) | Formulation of nefopam and its use in the treatment of pain | |
| US20070049552A1 (en) | Fluoroquinolone formulations and methods of making and using the same | |
| RU2005133665A (ru) | Применение производных 10-гидрокси-10,11-дигидрокарбамазепина для лечения аффективных расстройств | |
| RU2007119067A (ru) | Средство для лечения синдрома раздраженного кишечника с преобладанием диареи | |
| JP2014534229A5 (ru) | ||
| JP2019131596A5 (ru) | ||
| JP7110196B2 (ja) | カルバメート化合物を含む非経口用液剤 | |
| JP2017514829A5 (ru) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20120118 |